REDWOOD CITY, Calif.,
Jan. 3, 2017 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
Kim Popovits, chairman of the board, chief executive officer and
president, will present at the 35th Annual J.P. Morgan
Healthcare Conference at the Westin St. Francis Hotel in
San Francisco on Monday, January 9, 2017 at 11:00 a.m. Pacific Time.
To access the live and subsequently archived webcast of the
presentation, go to the Investor Relations section of the company's
web site at http://investor.genomichealth.com. Please connect to
the web site at least 15 minutes prior to the presentation to allow
for any software download that may be necessary. An archived replay
will be available for three months beginning 24 hours after the
live presentation.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading
provider of genomic-based diagnostic tests that help optimize
cancer care by addressing the overtreatment of the disease, one of
the greatest issues in healthcare today. With its Oncotype IQ™
Genomic Intelligence Platform, the company is applying its
world-class scientific and commercial expertise and infrastructure
to lead the translation of clinical and genomic big data into
actionable results for treatment planning throughout the cancer
patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype DX
gene expression tests that have been used to guide treatment
decisions for more than 700,000 cancer patients worldwide. Genomic
Health is expanding its test portfolio to include additional
liquid- and tissue-based tests, including the recently launched
Oncotype SEQ® Liquid Select assay. The company is based
in Redwood City, California, with international
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and the other risks set forth in the company's filings with
the Securities and Exchange Commission, including the risks
set forth in the company's quarterly report on Form 10-Q for the
quarter ended September 30, 2016. These forward-looking
statements speak only as of the date hereof. Genomic
Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are
trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-F
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-300383964.html
SOURCE Genomic Health, Inc.